Key terms

About ANAB

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANAB news

Apr 11 5:35am ET AnaptysBio initiated with an Overweight at Wells Fargo Mar 31 10:51am ET AnaptysBio price target lowered to $28 from $30 at JPMorgan Mar 18 8:35am ET 5 Stocks that Analysts Love in March 2024 Mar 18 7:45am ET Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB) Mar 12 9:02am ET Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD) Mar 12 8:08am ET Wedbush upgrades AnaptysBio to Outperform into clinical catalysts Mar 12 6:40am ET Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS) Mar 12 6:06am ET AnaptysBio upgraded to Outperform from Neutral at Wedbush Mar 12 5:47am ET J.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB) Mar 11 7:25pm ET Strong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial Health Mar 11 4:19pm ET AnaptysBio reports Q4 EPS ($1.59), consensus ($1.60) Feb 26 7:09am ET AnaptysBio initiated with a Buy at BTIG Feb 21 9:51am ET Palo Alto Networks, Home Depot downgraded: Wall Street’s top analyst calls Feb 20 4:12pm ET AnaptysBio initiated with a Buy at Stifel Feb 16 9:37am ET UPS upgraded, Nike downgraded: Wall Street’s top analyst calls Feb 16 4:56am ET AnaptysBio Buy Rating: Strategic Assets and Imminent Milestones Underscore Investment Potential Feb 16 4:51am ET AnaptysBio initiated with an Overweight at Piper Sandler

No recent press releases are available for ANAB

ANAB Financials

1-year income & revenue

Key terms

ANAB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANAB Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms